APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Injectable Drugs For Type-2 Diabete

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Injectable Drugs For Type-2 Diabete Market Outlook and Growth Opportunities 2026

Report ID 17400310042 January 2026197 pages

Choose your research edition.

Industry ResearchInjectable Drugs For Type-2 Diabete Industry Research Report 2026114 pages · $2,950 USDIndustry Growth & TrendsGlobal Injectable Drugs For Type-2 Diabete Industry Growth and Trends Forecast to 203288 pages · $3,450 USDMarket StructureGlobal Injectable Drugs For Type-2 Diabete Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Injectable Drugs For Type-2 Diabete Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Injectable Drugs For Type-2 Diabete Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Injectable Drugs For Type-2 Diabete market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Injectable Drugs For Type-2 Diabete is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Injectable Drugs For Type-2 Diabete is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Injectable Drugs For Type-2 Diabete is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Injectable Drugs For Type-2 Diabete market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Injectable Drugs For Type-2 Diabete market include Sanofi, Merck, Eli Lilly, GSK, AstraZeneca, Novo Nordisk and Boehringer Ingelheim, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Injectable Drugs For Type-2 Diabete market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Injectable Drugs For Type-2 Diabete and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Injectable Drugs For Type-2 Diabete revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Injectable Drugs For Type-2 Diabete market.

Injectable Drugs For Type-2 Diabete Segment by Company

Sanofi

Merck

Eli Lilly

GSK

AstraZeneca

Novo Nordisk

Boehringer Ingelheim

Injectable Drugs For Type-2 Diabete Segment by Type

Exenatide

Liragultide

Pramlintide

Insulin

Others

Injectable Drugs For Type-2 Diabete Segment by Application

Retail Pharmacy

Online Pharmacy

Hospital Pharmacy

Others

Injectable Drugs For Type-2 Diabete Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Injectable Drugs For Type-2 Diabete status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Injectable Drugs For Type-2 Diabete key companies, revenue, market share, and recent developments.

3. To split the Injectable Drugs For Type-2 Diabete breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Injectable Drugs For Type-2 Diabete market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Injectable Drugs For Type-2 Diabete significant trends, drivers, influence factors in global and regions.

6. To analyze Injectable Drugs For Type-2 Diabete competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Injectable Drugs For Type-2 Diabete market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Injectable Drugs For Type-2 Diabete and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Injectable Drugs For Type-2 Diabete.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Injectable Drugs For Type-2 Diabete industry.

Chapter 3: Detailed analysis of Injectable Drugs For Type-2 Diabete company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Injectable Drugs For Type-2 Diabete in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Injectable Drugs For Type-2 Diabete in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Injectable Drugs For Type-2 Diabete Industry Trends Table 2. Injectable Drugs For Type-2 Diabete Industry Drivers Table 3. Injectable Drugs For Type-2 Diabete Industry Opportunities and Challenges Table 4. Injectable Drugs For Type-2 Diabete Industry Restraints Table 5. Global Injectable Drugs For Type-2 Diabete Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Injectable Drugs For Type-2 Diabete Revenue Share by Company (2021-2026) Table 7. Global Injectable Drugs For Type-2 Diabete Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Injectable Drugs For Type-2 Diabete Key Company Manufacturing Base & Headquarters Table 9. Global Injectable Drugs For Type-2 Diabete Company, Product Type & Application Table 10. Global Injectable Drugs For Type-2 Diabete Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Injectable Drugs For Type-2 Diabete by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Exenatide Table 15. Significant Companies of Liragultide Table 16. Significant Companies of Pramlintide Table 17. Significant Companies of Insulin Table 18. Significant Companies of Others Table 19. Global Injectable Drugs For Type-2 Diabete Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Injectable Drugs For Type-2 Diabete Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Injectable Drugs For Type-2 Diabete Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Injectable Drugs For Type-2 Diabete Sales Value Share by Type (2021-2026) Table 23. Global Injectable Drugs For Type-2 Diabete Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Retail Pharmacy Table 25. Significant Companies of Online Pharmacy Table 26. Significant Companies of Hospital Pharmacy Table 27. Significant Companies of Others Table 28. Global Injectable Drugs For Type-2 Diabete Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Injectable Drugs For Type-2 Diabete Sales Value by Application (2021-2026) & (US$ Million) Table 30. Global Injectable Drugs For Type-2 Diabete Sales Value by Application (2027-2032) & (US$ Million) Table 31. Global Injectable Drugs For Type-2 Diabete Sales Value Share by Application (2021-2026) Table 32. Global Injectable Drugs For Type-2 Diabete Sales Value Share by Application (2027-2032) Table 33. Global Injectable Drugs For Type-2 Diabete Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Injectable Drugs For Type-2 Diabete Sales Value by Region (2021-2026) & (US$ Million) Table 35. Global Injectable Drugs For Type-2 Diabete Sales Value Share by Region (2021-2026) Table 36. Global Injectable Drugs For Type-2 Diabete Sales Value by Region (2027-2032) & (US$ Million) Table 37. Global Injectable Drugs For Type-2 Diabete Sales Value Share by Region (2027-2032) Table 38. Global Injectable Drugs For Type-2 Diabete Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Injectable Drugs For Type-2 Diabete Sales Value by Country (2021-2026) & (US$ Million) Table 40. Global Injectable Drugs For Type-2 Diabete Sales Value Market Share by Country (2021-2026) Table 41. Global Injectable Drugs For Type-2 Diabete Sales Value by Country (2027-2032) & (US$ Million) Table 42. Global Injectable Drugs For Type-2 Diabete Sales Value Market Share by Country (2027-2032) Table 43. Sanofi Company Information Table 44. Sanofi Business Overview Table 45. Sanofi Injectable Drugs For Type-2 Diabete Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Sanofi Injectable Drugs For Type-2 Diabete Product Portfolio Table 47. Sanofi Recent Development Table 48. Merck Company Information Table 49. Merck Business Overview Table 50. Merck Injectable Drugs For Type-2 Diabete Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Merck Injectable Drugs For Type-2 Diabete Product Portfolio Table 52. Merck Recent Development Table 53. Eli Lilly Company Information Table 54. Eli Lilly Business Overview Table 55. Eli Lilly Injectable Drugs For Type-2 Diabete Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Eli Lilly Injectable Drugs For Type-2 Diabete Product Portfolio Table 57. Eli Lilly Recent Development Table 58. GSK Company Information Table 59. GSK Business Overview Table 60. GSK Injectable Drugs For Type-2 Diabete Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. GSK Injectable Drugs For Type-2 Diabete Product Portfolio Table 62. GSK Recent Development Table 63. AstraZeneca Company Information Table 64. AstraZeneca Business Overview Table 65. AstraZeneca Injectable Drugs For Type-2 Diabete Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. AstraZeneca Injectable Drugs For Type-2 Diabete Product Portfolio Table 67. AstraZeneca Recent Development Table 68. Novo Nordisk Company Information Table 69. Novo Nordisk Business Overview Table 70. Novo Nordisk Injectable Drugs For Type-2 Diabete Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Novo Nordisk Injectable Drugs For Type-2 Diabete Product Portfolio Table 72. Novo Nordisk Recent Development Table 73. Boehringer Ingelheim Company Information Table 74. Boehringer Ingelheim Business Overview Table 75. Boehringer Ingelheim Injectable Drugs For Type-2 Diabete Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Boehringer Ingelheim Injectable Drugs For Type-2 Diabete Product Portfolio Table 77. Boehringer Ingelheim Recent Development Table 78. Research Programs/Design for This Report Table 79. Authors List of This Report Table 80. Secondary Sources Table 81. Primary Sources List of Figures Figure 1. Injectable Drugs For Type-2 Diabete Product Image Figure 2. Global Injectable Drugs For Type-2 Diabete Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Injectable Drugs For Type-2 Diabete Market Size (2021-2032) & (US$ Million) Figure 4. Global Injectable Drugs For Type-2 Diabete Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Exenatide Image Figure 8. Liragultide Image Figure 9. Pramlintide Image Figure 10. Insulin Image Figure 11. Others Image Figure 12. Global Injectable Drugs For Type-2 Diabete Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Injectable Drugs For Type-2 Diabete Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Injectable Drugs For Type-2 Diabete Sales Value Share by Type (2021-2032) Figure 15. Retail Pharmacy Image Figure 16. Online Pharmacy Image Figure 17. Hospital Pharmacy Image Figure 18. Others Image Figure 19. Global Injectable Drugs For Type-2 Diabete Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Injectable Drugs For Type-2 Diabete Sales Value Share 2021 VS 2025 VS 2032 Figure 21. Global Injectable Drugs For Type-2 Diabete Sales Value Share by Application (2021-2032) Figure 22. Global Injectable Drugs For Type-2 Diabete Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 23. Global Injectable Drugs For Type-2 Diabete Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 24. North America Injectable Drugs For Type-2 Diabete Sales Value (2021-2032) & (US$ Million) Figure 25. North America Injectable Drugs For Type-2 Diabete Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Europe Injectable Drugs For Type-2 Diabete Sales Value (2021-2032) & (US$ Million) Figure 27. Europe Injectable Drugs For Type-2 Diabete Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Asia-Pacific Injectable Drugs For Type-2 Diabete Sales Value (2021-2032) & (US$ Million) Figure 29. Asia-Pacific Injectable Drugs For Type-2 Diabete Sales Value Share by Country (%), 2025 VS 2032 Figure 30. South America Injectable Drugs For Type-2 Diabete Sales Value (2021-2032) & (US$ Million) Figure 31. South America Injectable Drugs For Type-2 Diabete Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Middle East & Africa Injectable Drugs For Type-2 Diabete Sales Value (2021-2032) & (US$ Million) Figure 33. Middle East & Africa Injectable Drugs For Type-2 Diabete Sales Value Share by Country (%), 2025 VS 2032 Figure 34. USA Injectable Drugs For Type-2 Diabete Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. USA Injectable Drugs For Type-2 Diabete Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. USA Injectable Drugs For Type-2 Diabete Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Canada Injectable Drugs For Type-2 Diabete Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Canada Injectable Drugs For Type-2 Diabete Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Canada Injectable Drugs For Type-2 Diabete Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Mexico Injectable Drugs For Type-2 Diabete Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Mexico Injectable Drugs For Type-2 Diabete Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Mexico Injectable Drugs For Type-2 Diabete Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Germany Injectable Drugs For Type-2 Diabete Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Germany Injectable Drugs For Type-2 Diabete Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Germany Injectable Drugs For Type-2 Diabete Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. France Injectable Drugs For Type-2 Diabete Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. France Injectable Drugs For Type-2 Diabete Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. France Injectable Drugs For Type-2 Diabete Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. U.K. Injectable Drugs For Type-2 Diabete Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. U.K. Injectable Drugs For Type-2 Diabete Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. U.K. Injectable Drugs For Type-2 Diabete Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Italy Injectable Drugs For Type-2 Diabete Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Italy Injectable Drugs For Type-2 Diabete Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Italy Injectable Drugs For Type-2 Diabete Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Spain Injectable Drugs For Type-2 Diabete Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Spain Injectable Drugs For Type-2 Diabete Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Spain Injectable Drugs For Type-2 Diabete Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Russia Injectable Drugs For Type-2 Diabete Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Russia Injectable Drugs For Type-2 Diabete Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Russia Injectable Drugs For Type-2 Diabete Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Netherlands Injectable Drugs For Type-2 Diabete Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Netherlands Injectable Drugs For Type-2 Diabete Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Netherlands Injectable Drugs For Type-2 Diabete Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Nordic Countries Injectable Drugs For Type-2 Diabete Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Nordic Countries Injectable Drugs For Type-2 Diabete Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Nordic Countries Injectable Drugs For Type-2 Diabete Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. China Injectable Drugs For Type-2 Diabete Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. China Injectable Drugs For Type-2 Diabete Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. China Injectable Drugs For Type-2 Diabete Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Japan Injectable Drugs For Type-2 Diabete Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Japan Injectable Drugs For Type-2 Diabete Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Japan Injectable Drugs For Type-2 Diabete Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. South Korea Injectable Drugs For Type-2 Diabete Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. South Korea Injectable Drugs For Type-2 Diabete Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. South Korea Injectable Drugs For Type-2 Diabete Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. India Injectable Drugs For Type-2 Diabete Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. India Injectable Drugs For Type-2 Diabete Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. India Injectable Drugs For Type-2 Diabete Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Australia Injectable Drugs For Type-2 Diabete Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Australia Injectable Drugs For Type-2 Diabete Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Australia Injectable Drugs For Type-2 Diabete Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Southeast Asia Injectable Drugs For Type-2 Diabete Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Southeast Asia Injectable Drugs For Type-2 Diabete Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Southeast Asia Injectable Drugs For Type-2 Diabete Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Brazil Injectable Drugs For Type-2 Diabete Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Brazil Injectable Drugs For Type-2 Diabete Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Brazil Injectable Drugs For Type-2 Diabete Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Argentina Injectable Drugs For Type-2 Diabete Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Argentina Injectable Drugs For Type-2 Diabete Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Argentina Injectable Drugs For Type-2 Diabete Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Chile Injectable Drugs For Type-2 Diabete Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Chile Injectable Drugs For Type-2 Diabete Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Chile Injectable Drugs For Type-2 Diabete Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Colombia Injectable Drugs For Type-2 Diabete Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Colombia Injectable Drugs For Type-2 Diabete Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Colombia Injectable Drugs For Type-2 Diabete Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Peru Injectable Drugs For Type-2 Diabete Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Peru Injectable Drugs For Type-2 Diabete Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Peru Injectable Drugs For Type-2 Diabete Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Injectable Drugs For Type-2 Diabete Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Saudi Arabia Injectable Drugs For Type-2 Diabete Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Saudi Arabia Injectable Drugs For Type-2 Diabete Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Israel Injectable Drugs For Type-2 Diabete Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Israel Injectable Drugs For Type-2 Diabete Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Israel Injectable Drugs For Type-2 Diabete Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. UAE Injectable Drugs For Type-2 Diabete Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. UAE Injectable Drugs For Type-2 Diabete Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. UAE Injectable Drugs For Type-2 Diabete Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Turkey Injectable Drugs For Type-2 Diabete Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Turkey Injectable Drugs For Type-2 Diabete Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Turkey Injectable Drugs For Type-2 Diabete Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Iran Injectable Drugs For Type-2 Diabete Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Iran Injectable Drugs For Type-2 Diabete Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Iran Injectable Drugs For Type-2 Diabete Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Egypt Injectable Drugs For Type-2 Diabete Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Egypt Injectable Drugs For Type-2 Diabete Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Egypt Injectable Drugs For Type-2 Diabete Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Years Considered Figure 119. Research Process Figure 120. Key Executives Interviewed

Scope & coverage.

Types
  • Exenatide
  • Liragultide
  • Pramlintide
  • Insulin
  • Others
Applications
  • Retail Pharmacy
  • Online Pharmacy
  • Hospital Pharmacy
  • Others
Companies covered
  • Sanofi
  • Merck
  • Eli Lilly
  • GSK
  • AstraZeneca
  • Novo Nordisk
  • Boehringer Ingelheim

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Injectable Drugs For Type-2 Diabete Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Injectable Drugs For Type-2 Diabete Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Injectable Drugs For Type-2 Diabete Market Dynamics
  1. 2.1 Injectable Drugs For Type-2 Diabete Industry Trends
  2. 2.2 Injectable Drugs For Type-2 Diabete Industry Drivers
  3. 2.3 Injectable Drugs For Type-2 Diabete Industry Opportunities and Challenges
  4. 2.4 Injectable Drugs For Type-2 Diabete Industry Restraints
3 Injectable Drugs For Type-2 Diabete Market by Company
  1. 3.1 Global Injectable Drugs For Type-2 Diabete Company Revenue Ranking in 2025
  2. 3.2 Global Injectable Drugs For Type-2 Diabete Revenue by Company (2021-2026)
  3. 3.3 Global Injectable Drugs For Type-2 Diabete Company Ranking (2024-2026)
  4. 3.4 Global Injectable Drugs For Type-2 Diabete Company Manufacturing Base and Headquarters
  5. 3.5 Global Injectable Drugs For Type-2 Diabete Company Product Type and Application
  6. 3.6 Global Injectable Drugs For Type-2 Diabete Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Injectable Drugs For Type-2 Diabete Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Injectable Drugs For Type-2 Diabete Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Injectable Drugs For Type-2 Diabete Market by Type
  1. 4.1 Injectable Drugs For Type-2 Diabete Type Introduction
  2. 4.1.1 Exenatide
  3. 4.1.2 Liragultide
  4. 4.1.3 Pramlintide
  5. 4.1.4 Insulin
  6. 4.1.5 Others
  7. 4.2 Global Injectable Drugs For Type-2 Diabete Sales Value by Type
  8. 4.2.1 Global Injectable Drugs For Type-2 Diabete Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Injectable Drugs For Type-2 Diabete Sales Value by Type (2021-2032)
  10. 4.2.3 Global Injectable Drugs For Type-2 Diabete Sales Value Share by Type (2021-2032)
5 Injectable Drugs For Type-2 Diabete Market by Application
  1. 5.1 Injectable Drugs For Type-2 Diabete Application Introduction
  2. 5.1.1 Retail Pharmacy
  3. 5.1.2 Online Pharmacy
  4. 5.1.3 Hospital Pharmacy
  5. 5.1.4 Others
  6. 5.2 Global Injectable Drugs For Type-2 Diabete Sales Value by Application
  7. 5.2.1 Global Injectable Drugs For Type-2 Diabete Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Injectable Drugs For Type-2 Diabete Sales Value by Application (2021-2032)
  9. 5.2.3 Global Injectable Drugs For Type-2 Diabete Sales Value Share by Application (2021-2032)
6 Injectable Drugs For Type-2 Diabete Regional Value Analysis
  1. 6.1 Global Injectable Drugs For Type-2 Diabete Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Injectable Drugs For Type-2 Diabete Sales Value by Region (2021-2032)
  3. 6.2.1 Global Injectable Drugs For Type-2 Diabete Sales Value by Region: 2021-2026
  4. 6.2.2 Global Injectable Drugs For Type-2 Diabete Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Injectable Drugs For Type-2 Diabete Sales Value (2021-2032)
  7. 6.3.2 North America Injectable Drugs For Type-2 Diabete Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Injectable Drugs For Type-2 Diabete Sales Value (2021-2032)
  10. 6.4.2 Europe Injectable Drugs For Type-2 Diabete Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Injectable Drugs For Type-2 Diabete Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Injectable Drugs For Type-2 Diabete Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Injectable Drugs For Type-2 Diabete Sales Value (2021-2032)
  16. 6.6.2 South America Injectable Drugs For Type-2 Diabete Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Injectable Drugs For Type-2 Diabete Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Injectable Drugs For Type-2 Diabete Sales Value Share by Country, 2025 VS 2032
7 Injectable Drugs For Type-2 Diabete Country-level Value Analysis
  1. 7.1 Global Injectable Drugs For Type-2 Diabete Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Injectable Drugs For Type-2 Diabete Sales Value by Country (2021-2032)
  3. 7.2.1 Global Injectable Drugs For Type-2 Diabete Sales Value by Country (2021-2026)
  4. 7.2.2 Global Injectable Drugs For Type-2 Diabete Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Injectable Drugs For Type-2 Diabete Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Injectable Drugs For Type-2 Diabete Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Injectable Drugs For Type-2 Diabete Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Injectable Drugs For Type-2 Diabete Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Injectable Drugs For Type-2 Diabete Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Injectable Drugs For Type-2 Diabete Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Injectable Drugs For Type-2 Diabete Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Injectable Drugs For Type-2 Diabete Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Injectable Drugs For Type-2 Diabete Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Injectable Drugs For Type-2 Diabete Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Injectable Drugs For Type-2 Diabete Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Injectable Drugs For Type-2 Diabete Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Injectable Drugs For Type-2 Diabete Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Injectable Drugs For Type-2 Diabete Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Injectable Drugs For Type-2 Diabete Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Injectable Drugs For Type-2 Diabete Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Injectable Drugs For Type-2 Diabete Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Injectable Drugs For Type-2 Diabete Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Injectable Drugs For Type-2 Diabete Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Injectable Drugs For Type-2 Diabete Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Injectable Drugs For Type-2 Diabete Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Injectable Drugs For Type-2 Diabete Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Injectable Drugs For Type-2 Diabete Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Injectable Drugs For Type-2 Diabete Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Injectable Drugs For Type-2 Diabete Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Injectable Drugs For Type-2 Diabete Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Injectable Drugs For Type-2 Diabete Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Injectable Drugs For Type-2 Diabete Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Injectable Drugs For Type-2 Diabete Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Injectable Drugs For Type-2 Diabete Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Injectable Drugs For Type-2 Diabete Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Injectable Drugs For Type-2 Diabete Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Injectable Drugs For Type-2 Diabete Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Injectable Drugs For Type-2 Diabete Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Injectable Drugs For Type-2 Diabete Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Injectable Drugs For Type-2 Diabete Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Injectable Drugs For Type-2 Diabete Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Injectable Drugs For Type-2 Diabete Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Injectable Drugs For Type-2 Diabete Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Injectable Drugs For Type-2 Diabete Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Injectable Drugs For Type-2 Diabete Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Injectable Drugs For Type-2 Diabete Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Injectable Drugs For Type-2 Diabete Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Injectable Drugs For Type-2 Diabete Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Injectable Drugs For Type-2 Diabete Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Injectable Drugs For Type-2 Diabete Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Injectable Drugs For Type-2 Diabete Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Injectable Drugs For Type-2 Diabete Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Injectable Drugs For Type-2 Diabete Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Injectable Drugs For Type-2 Diabete Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Injectable Drugs For Type-2 Diabete Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Injectable Drugs For Type-2 Diabete Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Injectable Drugs For Type-2 Diabete Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Injectable Drugs For Type-2 Diabete Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Injectable Drugs For Type-2 Diabete Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Injectable Drugs For Type-2 Diabete Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Injectable Drugs For Type-2 Diabete Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Injectable Drugs For Type-2 Diabete Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Injectable Drugs For Type-2 Diabete Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Injectable Drugs For Type-2 Diabete Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Injectable Drugs For Type-2 Diabete Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Injectable Drugs For Type-2 Diabete Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Injectable Drugs For Type-2 Diabete Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Injectable Drugs For Type-2 Diabete Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Injectable Drugs For Type-2 Diabete Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Injectable Drugs For Type-2 Diabete Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Injectable Drugs For Type-2 Diabete Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Injectable Drugs For Type-2 Diabete Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Injectable Drugs For Type-2 Diabete Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Injectable Drugs For Type-2 Diabete Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Injectable Drugs For Type-2 Diabete Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Injectable Drugs For Type-2 Diabete Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Injectable Drugs For Type-2 Diabete Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Injectable Drugs For Type-2 Diabete Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Injectable Drugs For Type-2 Diabete Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Injectable Drugs For Type-2 Diabete Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Injectable Drugs For Type-2 Diabete Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Injectable Drugs For Type-2 Diabete Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Injectable Drugs For Type-2 Diabete Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Injectable Drugs For Type-2 Diabete Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Injectable Drugs For Type-2 Diabete Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Injectable Drugs For Type-2 Diabete Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Injectable Drugs For Type-2 Diabete Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Injectable Drugs For Type-2 Diabete Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi
  2. 8.1.1 Sanofi Company Information
  3. 8.1.2 Sanofi Business Overview
  4. 8.1.3 Sanofi Injectable Drugs For Type-2 Diabete Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi Injectable Drugs For Type-2 Diabete Product Portfolio
  6. 8.1.5 Sanofi Recent Developments
  7. 8.2 Merck
  8. 8.2.1 Merck Company Information
  9. 8.2.2 Merck Business Overview
  10. 8.2.3 Merck Injectable Drugs For Type-2 Diabete Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Merck Injectable Drugs For Type-2 Diabete Product Portfolio
  12. 8.2.5 Merck Recent Developments
  13. 8.3 Eli Lilly
  14. 8.3.1 Eli Lilly Company Information
  15. 8.3.2 Eli Lilly Business Overview
  16. 8.3.3 Eli Lilly Injectable Drugs For Type-2 Diabete Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Eli Lilly Injectable Drugs For Type-2 Diabete Product Portfolio
  18. 8.3.5 Eli Lilly Recent Developments
  19. 8.4 GSK
  20. 8.4.1 GSK Company Information
  21. 8.4.2 GSK Business Overview
  22. 8.4.3 GSK Injectable Drugs For Type-2 Diabete Revenue and Gross Margin (2021-2026)
  23. 8.4.4 GSK Injectable Drugs For Type-2 Diabete Product Portfolio
  24. 8.4.5 GSK Recent Developments
  25. 8.5 AstraZeneca
  26. 8.5.1 AstraZeneca Company Information
  27. 8.5.2 AstraZeneca Business Overview
  28. 8.5.3 AstraZeneca Injectable Drugs For Type-2 Diabete Revenue and Gross Margin (2021-2026)
  29. 8.5.4 AstraZeneca Injectable Drugs For Type-2 Diabete Product Portfolio
  30. 8.5.5 AstraZeneca Recent Developments
  31. 8.6 Novo Nordisk
  32. 8.6.1 Novo Nordisk Company Information
  33. 8.6.2 Novo Nordisk Business Overview
  34. 8.6.3 Novo Nordisk Injectable Drugs For Type-2 Diabete Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Novo Nordisk Injectable Drugs For Type-2 Diabete Product Portfolio
  36. 8.6.5 Novo Nordisk Recent Developments
  37. 8.7 Boehringer Ingelheim
  38. 8.7.1 Boehringer Ingelheim Company Information
  39. 8.7.2 Boehringer Ingelheim Business Overview
  40. 8.7.3 Boehringer Ingelheim Injectable Drugs For Type-2 Diabete Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Boehringer Ingelheim Injectable Drugs For Type-2 Diabete Product Portfolio
  42. 8.7.5 Boehringer Ingelheim Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst